Scarica l'app Stockscreener
114.43
1.55%
1.75
Dopo l'orario di chiusura:
114.47
0.04
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$112.68
Aprire:
$113.23
Volume 24 ore:
7.40M
Relative Volume:
0.63
Capitalizzazione di mercato:
$198.01B
Reddito:
$46.59B
Utile/perdita netta:
$5.41B
Rapporto P/E:
36.99
EPS:
3.0938
Flusso di cassa netto:
$7.38B
1 W Prestazione:
+3.17%
1M Prestazione:
+13.66%
6M Prestazione:
+2.00%
1 anno Prestazione:
-12.82%
Intervallo 1D:
$112.91
$115.67
Intervallo di 1 settimana:
$109.35
$115.67
Portata 52W:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
114.43 | 194.98B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.98 | 127.10B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
94.13 | 117.87B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
52.01 | 73.14B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.28 | 52.44B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? - Yahoo Finance UK
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch - simplywall.st
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability - simplywall.st
Abbott settles appeal over $495 million infant formula verdict - Reuters
Abbott settles appeal of $495 million infant formula verdict - Investing.com
Richard W. Allen of Georgia’s 12th district makes significant trades in Abbott Laboratories and Advanced Micro Devices - Investing.com India
Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices. - Pluang
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst - The Globe and Mail
Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade) - Seeking Alpha
The Smartest Dividend ETF to Buy With $500 Right Now - The Globe and Mail
5 questions on Abbott’s glucose-ketone sensors - MedTech Dive
Abbott Laboratories raises earnings outlook aft... - Pluang
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool
Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-Term - Seeking Alpha
IFP Advisors Inc Purchases 176,649 Shares of Abbott Laboratories $ABT - MarketBeat
Thomasville National Bank Acquires Shares of 19,194 Abbott Laboratories $ABT - MarketBeat
Smith & Nephew drops 3.5% as finance chief quits - proactiveinvestors.co.uk
Allied Investment Advisors LLC Buys 17,762 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories stock holds above $110 as consensus target stays higher - ad-hoc-news.de
Sibionics Loses 2nd Bid At Nixing Abbott Patent - Law360
Abbott (NYSE:ABT) Valuation Focus Grows With Lingo AI Expansion - Kalkine Media
Abbott and NACHC Launch Multi-Year Initiative to Embed Nutrition Into Primary Care at Community Health Centers - Nutritional Outlook
Abbott (ABT) Stock May Be 27% Undervalued As Lingo AI Tie Up Grows - simplywall.st
Moody Lynn Lieberson & Walker LLC Has $22.52 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Prevail Innovative Wealth Advisors LLC Invests $2.83 Million in Abbott Laboratories $ABT - MarketBeat
Liberty Capital Management Inc. Invests $3.14 Million in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Has $7.06 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Holdings Lowered by Diversified Trust Co. - MarketBeat
Harmony Asset Management LLC Takes Position in Abbott Laboratories $ABT - MarketBeat
GRIMES & Co WEALTH MANAGEMENT LLC Cuts Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Richard McCormick - MarketBeat
Abbott Business Networks, LLC shifts business model to consulting - The Laconia Daily Sun
Abbott and NACHC launch Food for Health to boos... - Pluang
Abbott (ABT) Stock Looks Reasonable On Earnings With Stronger Cash Flow - Yahoo Finance
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare - Chain Drug Review
What Does Abbott Laboratories (ABT) Gain From This New App Controlled Pump Rollout? - Yahoo Finance
Recent Report Shows That Rep. Richard Dean Dr McCormick Sold Up to $375K Worth of Abbott Laboratories Stock - Benzinga
MiniMed Inc And Abbott Laboratories Begin Shipping MiniMed Flex System With Instinct Sensor In United States - marketscreener.com
Abbott Laboratories (ABT) Investor Outlook: Navigating a 7.33% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
HM Payson & Co. Sells 15,789 Shares of Abbott Laboratories $ABT - MarketBeat
Cidel Asset Management Inc. Sells 184,792 Shares of Abbott Laboratories $ABT - MarketBeat
Fairvoy Private Wealth LLC Has $361,000 Stock Position in Abbott Laboratories $ABT - MarketBeat
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 20,339 Shares of Abbott Laboratories $ABT - MarketBeat
Fifth Third Wealth Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Asio Capital LLC Buys Shares of 37,689 Abbott Laboratories $ABT - MarketBeat
Park National Corp OH Lowers Stake in Abbott Laboratories $ABT - MarketBeat
Matrix Asset Advisors Inc. NY Invests $4.29 Million in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Revenue Breakdown – AQUISUK:ABLD - tradingview.com
Can Abbott Laboratories (ABT)’s Lingo Partnership With Alphabet (GOOG) Unlock a New Era of AI-Powered Health? - Yahoo Finance
Court Dismisses Amended Securities Complaint Against Abbott Laboratories - TipRanks
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):